GlassScriptPhysician profile
Catherine L Thomas
NPI 1689648370
$2,768.26
in general payments reported to CMS, 2019-2025
36 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $237 · 2021: $340 · 2022: $444 · 2023: $601 · 2024: $462 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.17 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $334.69 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $278.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $243.03 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $183.08 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $178.42 | 2019-2025 | Repatha |
| Novo Nordisk INC | $145.65 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $101.74 | 2019-2021 | |
| Dexcom, INC. | $82.55 | 2021-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $77.57 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.33 | 2020-2022 | |
| Allergan, INC. | $54.98 | 2020 | |
| Novartis Pharmaceuticals Corporation | $50.28 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.02 | 2022-2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $43.77 | 2023-2024 | Gvoke Hypopen |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $40.09 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $31.52 | 2022 | |
| Astellas Pharma US INC | $31.13 | 2021-2023 | Veozah |
| Endogastric Solutions, INC | $30.01 | 2024 | Esophyx |
| Recordati_rare_diseases_inc. | $22.78 | 2023 | Panhematin |
| Takeda Pharmaceuticals U.S.A., INC. | $21.38 | 2019 | |
| Horizon Therapeutics Plc | $20.58 | 2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $19.71 | 2022 | |
| Corcept Therapeutics | $19.28 | 2024 | Korlym |
| Sanofi Pasteur INC. | $17.62 | 2023 | |
| Almatica Pharma LLC | $16.77 | 2022 | |
| Pulmonx Corporation | $16.26 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Vifor Pharma, INC. | $15.13 | 2019 | |
| Sumitomo Pharma America, INC. | $14.54 | 2023 | Gemtesa |
| Radius Health, INC. | $14.49 | 2021 | |
| Eisai INC. | $14.30 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.78 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $12.59 | 2019 | |
| Daiichi Sankyo INC. | $12.55 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.47 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.